Atopic dermatitis is a familial, chronic relapsing inflammatory skin disease characterized by intense itching, dry skin, with inflammation and exudation that commonly presents during early infancy and childhood, but can persist or start in adulthood.
It is also referred to as atopic eczema.
It is one of the most common skin diseases afflicting both adults and children.
Managing paediatric atopic dermatitis remains a huge challenge mainly because of noncompliance to treatment, but this challenge can be addressed by prescribing nonsteroidal, noncalcineurin inhibitor agents providing epidermal repair therapy, according to an expert who spoke at the 23rd Asian Australasian Regional Conference of Dermatology (RCD 2018) held in Surabaya, Indonesia.
Wake after sleep onset (WASO) is higher while sleep efficiency is lower among children with moderate-to-severe atopic dermatitis (AD) as compared with healthy controls, a recent study has shown. However, bedtime and wake time, sleep duration, and sleep onset latency are similar between the two groups.
Daily doses of the probiotic strains Bifidobacterium lactis CECT 8145, Bifidobacterium longum CECT 7347, and Lactobacillus casei CECT 9104 may reduce the SCORAD* index and need for topical steroids in children with moderate atopic dermatitis, according to a small study from Spain.
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.